Kits
S100A8/A9 (MRP8/14, Calprotectin, Mouse/Rat) ELISA
Kits
Description
Alternative names:
Calgranulin A: MRP8, S100A8, CP-10
Calgranulin B: MRP14, S100A9,
Calprotectin, MRP8/14: L1, (p8,14), p34
S100A8/S100A9 (MRP (8/14) is a calcium-binding protein secreted predominantly by
neutrophils and monocytes. Fecal S100A8/S100A9 is a marker for neoplasic and inflammatory
gastrointestinal diseases.
It is often difficult to distinguish between irritable bowel syndrome and chronic inflammatory
bowel disease. This leads in many cases to extensive and unnecessary
colonoscopic examinations. The S100A8/S100A9 test allows clear differentiation
between the two patient groups. Fecal S100A8/S100A9 levels correlate significantly
with histological and endoscopic assessment of disease activity in Morbus Crohn‘s disease
and ulcerative colitis as well as with the fecal excretion of indium-111-labelled
neutrophilic granulocytes that has been suggested as the “gold standard“ of disease
activity in inflammatory bowel disease. However, measuring 111-indium-labeled
granulocytes is very costly (patient’s hospitalization, analysis and disposal of isotopic
material) and is connected with radioactive exposition of the patients. For this reason,
a repeated application to children and pregnant women is not recommended.
Elevated levels of S100A8/S100A9 are a much better predictor of relapse than standard
inflammatory markers (CRP, ESR HB). Comparing this marker with standard fecal
occult blood screening in colourectal cancer demonstrates clearly the diagnostic
advantages of the fecal S100A8/S100A9 test. The parameter is of a high diagnostic
value: If the S100A8/S100A9 level in stool is low, there is a high probability that an
organic disease does not exist
Calgranulin A: MRP8, S100A8, CP-10
Calgranulin B: MRP14, S100A9,
Calprotectin, MRP8/14: L1, (p8,14), p34
S100A8/S100A9 (MRP (8/14) is a calcium-binding protein secreted predominantly by
neutrophils and monocytes. Fecal S100A8/S100A9 is a marker for neoplasic and inflammatory
gastrointestinal diseases.
It is often difficult to distinguish between irritable bowel syndrome and chronic inflammatory
bowel disease. This leads in many cases to extensive and unnecessary
colonoscopic examinations. The S100A8/S100A9 test allows clear differentiation
between the two patient groups. Fecal S100A8/S100A9 levels correlate significantly
with histological and endoscopic assessment of disease activity in Morbus Crohn‘s disease
and ulcerative colitis as well as with the fecal excretion of indium-111-labelled
neutrophilic granulocytes that has been suggested as the “gold standard“ of disease
activity in inflammatory bowel disease. However, measuring 111-indium-labeled
granulocytes is very costly (patient’s hospitalization, analysis and disposal of isotopic
material) and is connected with radioactive exposition of the patients. For this reason,
a repeated application to children and pregnant women is not recommended.
Elevated levels of S100A8/S100A9 are a much better predictor of relapse than standard
inflammatory markers (CRP, ESR HB). Comparing this marker with standard fecal
occult blood screening in colourectal cancer demonstrates clearly the diagnostic
advantages of the fecal S100A8/S100A9 test. The parameter is of a high diagnostic
value: If the S100A8/S100A9 level in stool is low, there is a high probability that an
organic disease does not exist